Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1780975136
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1700 E Cesar E Chavez Ave
Los Angeles, CA, 90033
Phone (323) 264-0430
Groups this clinician bills Medicare through
Medicare paid, 2024
$158K
6,710 services
Medicare patients, 2024
59
Average age 74
Drug cost, 2024
$13.5M
3,076 prescriptions
Company payments, 2025
$4,951
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Byung Lee was code 99213 (office e&m - established), 46 times for 27 patients. In total Byung Lee billed 6,710 services in 31 codes, and Medicare paid $158K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 46 | 27 | $61.00 | $2,806 |
| 99442 Telephone Services | Office | 46 | 31 | $66.82 | $3,074 |
By year: 2022 $157K for 3,616 services; 2023 $165K for 4,492 services; 2024 $158K for 6,710 services.
Medicare prescription drug claims, 2024
In 2024, the drug Byung Lee prescribed most often to Medicare patients was Anastrozole, with 427 prescriptions and refills. In total Byung Lee wrote 3,076 Medicare prescriptions that cost $13.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 427 | 1,160 | 134 | $7,772 |
| Procrit Epoetin Alfa | 236 | 244 | 70 | $763K |
| Prednisone Generic | 225 | 251 | 49 | $883 |
| Hydroxyurea Generic | 148 | 264 | 33 | $2,368 |
| Abiraterone Acetate Generic | 141 | 153 | 26 | $262K |
| Revlimid Lenalidomide | 131 | 131 | 14 | $2.2M |
| Calquence Acalabrutinib Maleate | 106 | 106 | 14 | $1.5M |
| Ondansetron Odt Ondansetron | 97 | 97 | 72 | $2,310 |
| Dexamethasone Generic | 90 | 116 | 22 | $805 |
| Eliquis Apixaban | 89 | 125 | 19 | $71K |
| Loperamide Loperamide Hcl | 89 | 89 | 56 | $519 |
| Imbruvica Ibrutinib | 86 | 86 | Under 11 | $1.3M |
| Tamoxifen Citrate Generic | 79 | 235 | 31 | $2,952 |
| Letrozole Generic | 77 | 208 | 30 | $1,821 |
| Jakafi Ruxolitinib Phosphate | 58 | 58 | Under 11 | $739K |
Brand drugs: 1,251 claims; generic drugs: 1,825 claims; opioid claims: 49.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Byung Lee $4,951 ($4,951 in general payments such as food, travel and fees) from 45 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,344.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 29 | $1,344 |
| Janssen Biotech, Inc. JNJ | 12 | $348 |
| Pfizer Inc. PFE | 11 | $276 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $259 |
| Eisai Inc. 4523.T | 10 | $204 |
| BeOne Medicines USA, Inc. ONC | 7 | $189 |
| Array Biopharma Inc PFE | 9 | $185 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $173 |
| Celgene Corporation BMY | 13 | $169 |
| Karyopharm Therapeutics Inc. KPTI | 4 | $107 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.